HYFT MindWalk Holdings Corp.
Debt Financing ·
MindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed.
The index change took effect after the U.S. market close on June 26, 2026. A Form F-3 filed on July 13, 2026 replaces an older shelf and includes a $50,000,000 at-the-market program.
The twelve-month program starts October 15, 2025. The company says it represents approximately 5% of the 46,154,188 common shares outstanding.
Revenue was $24.5 million in both fiscal 2025 and fiscal 2024, and the net loss widened to $30.2 million from $26.1 million. The release gives no date for the regained Nasdaq compliance.
Our latest story on this, dated Jul 6, 2026: "MindWalk added to Russell 3000E Index, then files $250,000,000 shelf". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 9, 2025: "MindWalk authorizes buyback of up to 2.3 million shares". The story links the filing or release it is based on. Read the story.
MindWalk Holdings Corp. trades under the ticker HYFT on NASDAQ.
MindWalk Holdings Corp. is listed on NASDAQ. Our directory also records these other listings: GETTEX:TQB0; LSX:A41GYL.
The SEC Central Index Key (CIK) for MindWalk Holdings Corp. is 1715925. Its filings are on SEC EDGAR.
46,711,866 shares as of 2026-04-30, per the cover page of its 20-F filed 2026-07-23.
Our directory records MindWalk Holdings Corp. under United States.
Our directory classifies MindWalk Holdings Corp. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for MindWalk Holdings Corp. is CA6026871054.
aibio.space lists MindWalk Holdings Corp. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
Our latest story on MindWalk Holdings, dated Sep 14, 2026: "MindWalk signs binding $30 million credit facility term sheet". MindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed. Source.
Our latest debt story, dated Sep 14, 2026: "MindWalk signs binding $30 million credit facility term sheet". MindWalk Holdings signed a binding term sheet with Sanabil (Cayman) for a revolving credit facility of up to $30 million at a fixed 7.00% annual rate. The definitive agreement is not yet signed. Source.
From our story of Jul 6, 2026: It also lists going-concern risk and the risk that the company may fail to remediate a material weakness. Source.
Our latest listing story, dated Jul 29, 2025: "ImmunoPrecise Antibodies (now MindWalk Holdings) reports fiscal 2025 results". Revenue was $24.5 million in both fiscal 2025 and fiscal 2024, and the net loss widened to $30.2 million from $26.1 million. The release gives no date for the regained Nasdaq compliance. Source.
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 424B5. Source
Announced a share repurchase program. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio